Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Lilly To Acquire Akouos; Acquisition Valued At $487M Plus Contingent Value Right For Aggregate Amount Of $610M

Proposed acquisition will accelerate gene therapies that aim to restore, improve, and preserve hearing for patients living with disabling hearing loss worldwide Transaction valued at approximately $487 million plus a
byBenzinga Newsdesk
October 18, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Proposed acquisition will accelerate gene therapies that aim to restore, improve, and preserve hearing for patients living with disabling hearing loss worldwide

Transaction valued at approximately $487 million plus a contingent value right for an aggregate amount up to approximately $610 million

INDIANAPOLIS and BOSTON, Oct. 18, 2022 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) and Akouos, Inc. (NASDAQ:AKUS) today announced a definitive agreement for Lilly to acquire Akouos, a precision genetic medicine company that is developing a portfolio of first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

FTI Consulting to Acquire BOLD; Terms Not Disclosed

By Charles Gross
Today, 5:31 AM
FTI Consulting, Inc. (NYSE: FCN) today announced that it has entered into a definitive agreement to acquire BOLD, a leading restructuring, transactions, digital and transformation advisory firm in the Netherlands. The acquisition is expected to close during the first quarter of 2022. Terms of the transaction were not disclosed.

FCN